Literature DB >> 193851

Interaction of canine and swine lipoproteins with the low density lipoprotein receptor of fibroblasts as correlated with heparin/manganese precipitability.

R W Mahley, T L Innerarity.   

Abstract

Canine HDL1 and canine and swine HDLc were fractionated into several lipoprotein subpopulations by heparin/manganese precipitation. The ability of the various subfractions of HDL1 or HDLc to compete with 125I-labeled low density lipoproteins (LDL) for binding and degradation by human fibroblasts was compared. The HDL1 or HDLc which precipitated at the lowest concentration of heparin (a concentration which precipitates LDL) were the most effective in competing with 125I-LDL for binding, internalization, and degradation. A striking characteristic of these lipoproteins was the occurrence of a prominence of the arginine-rich apoprotein. The HDL1 or HDLc subfractions which were not precipitated by heparin/managanese lacked detectable arginine-rich apoprotein and did not compete significantly with the 125I-LDL for binding and degradation. Furthermore, the lipid to protein ratio differed in the precipitable and nonprecipitable lipoproteins, with those which were most efficiently bound and degraded containing more cholesterol. Specific lipoprotein interaction with heparin and with the cell surface receptors may occur by a common mechanism; namely, through a positively charged region on the lipoprotein surface which may reside with the B and arginine-rich apoproteins.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 193851

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Role of an intramolecular contact on lipoprotein uptake by the LDL receptor.

Authors:  Zhenze Zhao; Peter Michaely
Journal:  Biochim Biophys Acta       Date:  2011-04-09

2.  Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDLc.

Authors:  R E Pitas; T L Innerarity; K S Arnold; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

3.  Biologically active low density lipoprotein in human peripheral lymph.

Authors:  D Reichl; N B Myant; M S Brown; J L Goldstein
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

4.  Visualization of primate high density lipoproteins isolated by density gradient ultracentrifugation.

Authors:  J L Hojnacki; R J Nicolosi; N Llansa; K C Hayes
Journal:  Lipids       Date:  1978-01       Impact factor: 1.880

Review 5.  Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.

Authors:  Amy S Shah; Lirong Tan; Jason Lu Long; W Sean Davidson
Journal:  J Lipid Res       Date:  2013-02-24       Impact factor: 5.922

6.  Uptake and degradation of iodine-labelled chylomicron remnant particles by monolayers of rat hepatocytes.

Authors:  C H Florén; A Nilsson
Journal:  Biochem J       Date:  1978-09-15       Impact factor: 3.857

7.  Apolipoprotein E synthesis in human kidney, adrenal gland, and liver.

Authors:  M L Blue; D L Williams; S Zucker; S A Khan; C B Blum
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

8.  The epidermal growth factor homology domain of the LDL receptor drives lipoprotein release through an allosteric mechanism involving H190, H562, and H586.

Authors:  Zhenze Zhao; Peter Michaely
Journal:  J Biol Chem       Date:  2008-08-03       Impact factor: 5.157

9.  Effects of dietary cholesterol and fatty acids on plasma lipoproteins.

Authors:  G Schonfeld; W Patsch; L L Rudel; C Nelson; M Epstein; R E Olson
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

10.  Role of apolipoprotein E-containing lipoproteins in abetalipoproteinemia.

Authors:  C B Blum; R J Deckelbaum; L D Witte; A R Tall; J Cornicelli
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.